MediSapiens, a Finnish developer and provider of Bio-IT solutions for research and biomedicine, is a partner in an international consortium aiming at developing personalized medicine applications using integrated genome and other health data. The consortium was founded and is headed by the Competence Centre on Health Technologies of Estonia (CCHT) in the framework of the Competence Centre program supported via Enterprise Estonia. Along with MediSapiens and CCHT, the other consortium members are the University of Tartu Estonian Genome Center (Estonia), Tallinn University of Technology eMedicine Laboratory (Estonia), BioEximi OÜ (Estonia), Duodecim Medical Publications Ltd. (Finland) and Coimbra Genomics (Portugal).

The first part of the project, “Assessment of terms for the development of clinically valid and commercially viable personalized medicine products and services,” aims at defining those personalized medicine products and services the consortium expects to bring to the market together, and exploring and selecting appropriate business models. This phase will be finalized by May 2016, and will be continued to subsequent research and development phases. In order to align the products and services with market needs and ensure clinical applicability, clinical experts will be invited to counsel the consortium. The project is co-financed by the European Regional Development Fund via Enterprise Estonia, the CCHT and its consortium partners.

“Our consortium has the potential for smooth development and application in Estonia and elsewhere,” said Prof. Anders Salumets, CEO of CCHT.